Woodline Partners LP Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Woodline Partners LP has made a significant investment of $11.14 million in ANI Pharmaceuticals, acquiring 166,448 shares and owning approximately 0.76% of the company.
• Insider trading activity saw both the CFO and CEO of ANI Pharmaceuticals sell a combined total of 106,960 shares valued at over $9.2 million, representing substantial reductions in their holdings.
• Equity analysts have a generally positive outlook on ANI Pharmaceuticals, with target prices raised to as high as $114 and a current consensus rating of "Buy."

Woodline Partners LP acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 166,448 shares of the specialty pharmaceutical company's stock, valued at approximately $11,144,000. Woodline Partners LP owned 0.76% of ANI Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Hohimer Wealth Management LLC raised its stake in ANI Pharmaceuticals by 5.2% during the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after buying an additional 247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after buying an additional 364 shares during the period. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth $28,000. GAMMA Investing LLC raised its stake in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. Finally, National Bank of Canada FI acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth $79,000. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $0.55 during midday trading on Wednesday, reaching $97.00. The company's stock had a trading volume of 38,511 shares, compared to its average volume of 374,019. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The business's 50 day moving average price is $80.84 and its two-hundred day moving average price is $70.28. The company has a market cap of $2.10 billion, a P/E ratio of -125.97 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period in the previous year, the business earned $1.02 earnings per share. The firm's quarterly revenue was up 53.2% on a year-over-year basis. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Antonio R. Pera sold 7,292 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $94.94, for a total value of $692,302.48. Following the completion of the sale, the director directly owned 22,660 shares in the company, valued at approximately $2,151,340.40. The trade was a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the completion of the sale, the chief operating officer owned 431,920 shares of the company's stock, valued at approximately $39,062,844.80. The trade was a 10.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 412,830 shares of company stock valued at $36,397,254 in the last quarter. Corporate insiders own 12.70% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Piper Sandler reaffirmed an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Guggenheim raised their price objective on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a "buy" rating in a research note on Monday, September 8th. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Finally, HC Wainwright lifted their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a "buy" rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $91.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.